Edition:
United States

Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

67.66EUR
23 Aug 2019
Change (% chg)

€-0.04 (-0.06%)
Prev Close
€67.70
Open
€67.80
Day's High
€68.16
Day's Low
€67.26
Volume
360,698
Avg. Vol
326,447
52-wk High
€81.48
52-wk Low
€67.20

Latest Key Developments (Source: Significant Developments)

UCB H1 Net Sales Increased To 2.2 Billion Euros
Thursday, 25 Jul 2019 01:00am EDT 

July 25 (Reuters) - UCB SA ::UCB HALF YEAR REPORT 2019: UCB'S STRONG PERFORMANCE ENABLES CONTINUED INVESTMENT INTO FUTURE GROWTH DRIVERS.H1 REVENUE REACHED EUR 2.3 BILLION (+2%, +4% CER(1)).H1 CIMZIA NET SALES EUR 782 MILLION VERSUS EUR 679 MILLION YEAR AGO.H1 UNDERLYING PROFITABILITY (REBITDA(3)) WAS EUR 724 MILLION (-9%, -1% CER) OR A RATIO OF 31%.H1 VIMPAT NET SALES EUR 371 MILLION VERSUS EUR 522 MILLION YEAR AGO.FINANCIAL OUTLOOK FOR 2019 CONFIRMED.H1 VIMPAT NET SALES EUR 622 MILLION VERSUS EUR 522 MILLION YEAR AGO.H1 KEPPRA NET SALE EUR 371 MILLION VERSUS EUR 392 MILLION YEAR AGO.H1 BRIVIACT NET SALES EUR 103 MILLION VERSUS EUR 60 MILLION YEAR AGO.H1 NEUPRO NET SALES EUR 158 MILLION VERSUS EUR 148 MILLION YEAR AGO.H1 REBITDA EUR 724 MILLION VERSUS EUR 794 MILLION YEAR AGO.OUTLOOK 2019 CONFIRMED.CFO TRANSITION IN 2020.CHIEF FINANCIAL OFFICER, DETLEF THIELGEN, WILL BE TRANSITIONING OUT WITHIN A YEAR FROM NOW. A SEARCH FOR A SUCCESSOR HAS JUST BEGUN..  Full Article

UCB H1 Revenue Up At 2.3 Billion Euros
Thursday, 25 Jul 2019 01:00am EDT 

July 25 (Reuters) - UCB SA ::H1 VIMPAT NET SALES EUR 622 MILLION VERSUS EUR 522 MILLION YEAR AGO.UCB HALF YEAR REPORT 2019: UCB'S STRONG PERFORMANCE ENABLES CONTINUED INVESTMENT INTO FUTURE GROWTH DRIVERS.H1 REVENUE REACHED EUR 2.3 BILLION (+2%, +4% CER(1)).H1 CIMZIA NET SALES EUR 782 MILLION VERSUS EUR 679 MILLION YEAR AGO.H1 UNDERLYING PROFITABILITY (REBITDA(3)) WAS EUR 724 MILLION (-9%, -1% CER) OR A RATIO OF 31%.FINANCIAL OUTLOOK FOR 2019 CONFIRMED.H1 KEPPRA NET SALE EUR 371 MILLION VERSUS EUR 392 MILLION YEAR AGO.H1 BRIVIACT NET SALES EUR 103 MILLION VERSUS EUR 60 MILLION YEAR AGO.H1 NEUPRO NET SALES EUR 158 MILLION VERSUS EUR 148 MILLION YEAR AGO.CFO TRANSITION IN 2020.CHIEF FINANCIAL OFFICER, DETLEF THIELGEN, WILL BE TRANSITIONING OUT WITHIN A YEAR FROM NOW. A SEARCH FOR A SUCCESSOR HAS JUST BEGUN..H1 VIMPAT NET SALES EUR 622 MILLION VERSUS EUR 522 MILLION YEAR AGO.  Full Article

UCB And Amgen Provide Regulatory Update On Status Of EVENITY in EU
Friday, 28 Jun 2019 01:12am EDT 

June 28 (Reuters) - UCB SA ::UCB AND AMGEN PROVIDE REGULATORY UPDATE ON STATUS OF EVENITY® (ROMOSOZUMAB) IN THE EU.COMPANIES INTEND TO SUBMIT A WRITTEN NOTICE FOR A RE-EXAMINATION BY THE CHMP.UCB AND AMGEN WERE INFORMED THAT CHMP OF EMA ADOPTED NEGATIVE OPINION ON MARKETING AUTHORISATION APPLICATION FOR EVENITY (ROMOSOZUMAB).  Full Article

Amgen Says CHMP OF EMA Adopted Negative Opinion On MAA For Evenity
Friday, 28 Jun 2019 01:00am EDT 

June 28 (Reuters) - Amgen Inc ::AMGEN AND UCB PROVIDE REGULATORY UPDATE ON STATUS OF EVENITY™ (ROMOSOZUMAB) IN THE EU.AMGEN - CHMP OF EMA ADOPTED NEGATIVE OPINION ON MARKETING AUTHORIZATION APPLICATION FOR EVENITY (ROMOSOZUMAB) FOR TREATMENT OF SEVERE OSTEOPOROSIS.AMGEN INC - COMPANIES INTEND TO SUBMIT A WRITTEN NOTICE FOR A RE-EXAMINATION BY CHMP.AMGEN INC - "DISAPPOINTED" WITH CHMP OPINION AND BELIEVE THAT BODY OF EVIDENCE SUBMITTED SUPPORTS A "POSITIVE BENEFIT".AMGEN INC - CONTINUE TO BELIEVE THAT EVENITY HAS A POSITIVE BENEFIT OF RISK PROFILE.AMGEN INC - RE-EXAMINATION PROCESS GIVES COS OPPORTUNITY TO CLARIFY POSITION ON SUBMITTED DATA.  Full Article

UCB Initiates Phase 1B US-Based Multicenter Clinical Trial In Parkinson’S Disease Patients
Tuesday, 28 May 2019 08:01am EDT 

May 28 (Reuters) - UCB SA ::UCB INITIATES PHASE 1B US-BASED MULTICENTER CLINICAL TRIAL IN PARKINSON’S DISEASE PATIENTS WITH UCB0599, A COMPOUND ARISING FROM THE NEUROPORE-UCB COLLABORATION.SAYS NEUROPORE WILL RECEIVE A $5 MILLION (USD) AWARD AS A RESULT OF ACHIEVING THIS MILESTONE..  Full Article

Amgen Inc - Evenity Receives Approval In Japan For Treatment Of Osteoporosis
Tuesday, 8 Jan 2019 04:00pm EST 

Jan 8 (Reuters) - Amgen Inc ::EVENITY(ROMOSOZUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF OSTEOPOROSIS IN PATIENTS AT HIGH RISK OF FRACTURE.AMGEN INC - EVENITY IN JAPAN IS BEING CO-DEVELOPED THROUGH STRATEGIC ALLIANCE WITH AMGEN ASTELLAS BIOPHARMA.AMGEN INC - JAPANESE MINISTRY OF HEALTH, LABOR AND WELFARE HAS GRANTED A MARKETING AUTHORIZATION FOR EVENITY.  Full Article

UCB 9-Month Revenue Increases To 3.4 Billion Euros
Tuesday, 30 Oct 2018 02:23am EDT 

Oct 30 (Reuters) - UCB SA ::FINANCIAL OUTLOOK 2018 CONFIRMED: REVENUE EXPECTED TO REACH € 4.5 - 4.6 BILLION.SEES 2018 RECURRING EBITDA REACHING EUR 1.3-1.4 BILLION.REVENUE FOR THE FIRST NINE MONTHS OF 2018 REACHED € 3.4 BILLION, +3% AT ACTUAL AND +6% AT CONSTANT EXCHANGE RATES (CER).REVENUE REACHED € 3.4 BILLION (+3%; +6% CER).RESEARCH AND DEVELOPMENT UPDATE: CIMZIA FILED FOR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA) IN THE U.S.RESEARCH AND DEVELOPMENT UPDATE: KEPPRA APPROVED AS MONOTHERAPY FOR EPILEPSY IN CHINA.RESEARCH AND DEVELOPMENT UPDATE: ROZANOLIXIZUMAB ACHIEVED POSITIVE RESULTS AND PROOF-OF-CONCEPT IN MYASTHENIA GRAVIS.  Full Article

UCB Receives CHMP Positive Opinion For Adjunctive Use Of Briviact
Friday, 1 Jun 2018 11:59am EDT 

June 1 (Reuters) - UCB SA ::RECEIVES CHMP POSITIVE OPINION FOR ADJUNCTIVE USE OF BRIVIACT.OPINION EXTENDS THERAPEUTIC INDICATION TO INCLUDE ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALISATION IN PATIENTS WITH EPILEPSY FROM 4 YEARS OF AGE..EUROPEAN COMMISSION IS EXPECTED TO MAKE A DECISION BASED ON THIS CHMP POSITIVE OPINION OVER THE COMING WEEKS.  Full Article

UCB FY Net Sales Up At ‍​4.18 Billion Euros
Thursday, 22 Feb 2018 02:23am EST 

Feb 22 (Reuters) - UCB SA ::FY: REVENUE EUR 4.53‍​ BILLION VERSUS EUR 4.43 BILLION IN REUTERS POLL, NET SALES EUR ‍​4.18 BILLION VERSUS EUR 3.83 BILLION YEAR AGO.FY: RECURRING EBITDA EUR ‍​1.38 BILLION VERSUS EUR 1.28 BILLION IN REUTERS POLL; VIMPAT NET SALES EUR ‍​976 MILLION VERSUS EUR 970 MILLION IN REUTERS POLL.FY: CIMZIA NET SALES EUR 1.42‍​ BILLION VERSUS EUR 1.40 BILLION IN REUTERS POLL; KEPPRA NET SALES EUR ‍​778 MILLION VERSUS EUR 795 MILLION IN REUTERS POLL.FY NEUPRO NET SALES EUR ‍​314 MILLION VERSUS EUR 312 MILLION IN REUTERS POLL.2018 REVENUE IS EXPECTED TO REACH APPROXIMATELY € 4.5 BILLION – EUR 4.6 BILLION‍​.2018 RECURRING EBITDA IN THE RANGE OF € 1.3 BILLION – EUR 1.4 BILLION.CORE EARNINGS PER SHARE EXPECTED BETWEEN € 4.30 – EUR, 4.70 BASED ON AN AVERAGE OF 188 MILLION SHARES OUTSTANDING.PROPOSES A DIVIDEND OF € 1.18 PER SHARE (GROSS), AN INCREASE BY THREE €-CENTS OR BY 2.6%.PROFIT FOR THE GROUP AMOUNTED TO € 771 MILLION (+42%) OF WHICH € 753 MILLION IS ATTRIBUTABLE TO UCB SHAREHOLDERS.  Full Article

UCB Announces That EMA Has Approved Label Change For Cimzia
Tuesday, 9 Jan 2018 01:13am EST 

Jan 9 (Reuters) - UCB SA ::EMA HAS APPROVED LABEL CHANGE FOR UCB’S CIMZIA.LABEL CHANGE MAKING IT FIRST ANTI-TNF FOR POTENTIAL USE IN WOMEN WITH CHRONIC RHEUMATIC DISEASE, DURING PREGNANCY AND BREASTFEEDING.  Full Article